Cytori: SCLERADEC-I Data Shows Sustained Benefit Of Cell Therapy - Quick Facts

(RTTNews) - Cytori Therapeutics, Inc. (CYTX) announced the finding of sustained benefit at two-year follow-up in the SCLERADEC-I trial of Cytori Cell Therapy in patients with hand dysfunction associated with scleroderma. The company said the two-year follow up data in the SCLERADEC-I trial, demonstrated sustained improvement in four key endpoints: Cochin Hand Function Score; Scleroderma Health Assessment Questionnaire; Raynaud's Condition Score; and hand pain.

The SCLERADEC-I trial is an investigator-initiated, open-label, 12 patient trial. Two follow-on, late-stage trials, STAR in the United States, and SCLERADEC-II in France, are currently enrolling patients.